Cyclo Therapeutics (NASDAQ:CYTH) Releases Earnings Results, Misses Estimates by $0.07 EPS

Cyclo Therapeutics (NASDAQ:CYTH – Get Your Free Report ) released its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports. Cyclo Therapeutics had a negative return on equity of 2,741.89% and a negative net margin of 1,720.76%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million.

Cyclo Therapeutics Stock Performance

Shares of CYTH stock opened at $1.26 on Friday. Cyclo Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.12. The company has a market cap of $36.06 million, a P/E ratio of -1.26 and a beta of -0.33. The stock has a 50 day moving average price of $1.21 and a two hundred day moving average price of $1.39.

Changes in Analyst Ratings

Several research firms have commented on CYTH. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Cyclo Therapeutics in a research note on Friday. Ascendiant Capital Markets initiated coverage on shares of Cyclo Therapeutics in a research report on Monday, April 22nd. They issued a “buy” rating and a $2.60 price target on the stock.

Check out our latest review of Cyclo Therapeutics

About Cyclo Therapeutics

(Get a free report)

Cyclo Therapeutics, Inc, a clinical-stage biotechnology company, is engaged in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug in Phase III clinical trials for the treatment of Niemann-Pick type C disease; and in phase IIb clinical trials for the treatment of Alzheimer’s disease.

Featured stories

Receive news and reviews for Cyclo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cyclo Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.